Sermorelin GHK is a combination-product description, not another name for plain sermorelin. Everlife, for example, markets a sublingual preparation combining sermorelin, GHK, and citrulline. Other compounded products may include glycine or different additional ingredients.
The complete formulation matters. Research about one ingredient cannot establish that the finished combination has better absorption, better skin results, or fewer adverse effects. Each of those claims needs appropriate evidence for the product being offered.
Read every ingredient on the label. A blend is a separate treatment question, not plain sermorelin with guaranteed extra benefits.
What the names tell you—and what they do not
GHK refers to a small peptide; GHK-Cu refers to its copper complex. Glycine and citrulline are amino acids, not interchangeable names for GHK. A marketing page may abbreviate the ingredients, so the pharmacy label should resolve the exact identity.
Ask whether the listed quantity is for each ingredient, a single tablet, a milliliter, or an entire container. Do not assume a total blend strength specifies the amount of sermorelin. The dosage-label guide explains why that distinction can prevent confusion.
A collection of ingredient studies is not a blend trial
A seller may cite a skin study for one ingredient, a hormone study for another, and a metabolism study for a third. Even if each citation is accurately described, that collection does not establish the outcomes of the combined product at its actual route and amounts.
Look for whether the proposed finished preparation was tested in humans against a suitable comparator. Laboratory, animal, topical, and injectable results answer different questions. A testimonial about a mint cannot close those gaps. Our Everlife review applies this distinction to a specific advertised offering.
Route-specific safety language matters
FDA has described concerns about compounded injectable GHK-Cu, including potential immunogenicity and limited human safety information. Those concerns should be reported with their route intact; they are not a measured adverse-event rate for a sublingual blend.
At the same time, the lack of a matching warning for a particular oral product is not proof of safety or clinical benefit. Ask the clinician and pharmacist for the evidence that applies to the exact preparation, especially if you use other hormones, peptides, or supplements.
Questions that make a blend easier to evaluate
Request the full ingredient list, administration instructions, pharmacy identity, and reason each ingredient is included. Ask whether there is direct evidence for the finished combination and how the team would investigate an adverse effect when several ingredients are present.
Compare the complete cost with the intended benefit, not just the number of ingredients. A longer label does not necessarily make a better treatment. Read tablets versus injections and skin and hair claims for two common decisions surrounding these products.
Sources behind this article
Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.
- Everlife: Sermorelin GHKProvider primary source · Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.
- FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
- Sigalos and Pastuszak: Safety and efficacy of growth hormone secretagoguesClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- FDA: Peptide compounding safety concernsClinical or regulatory reference · Checked September 20, 2026. Findings apply to the specified molecule, route, and population.
- FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.